Insider Selling: PhotoMedex CEO Sells 100,000 Shares of Stock (PHMD)
PhotoMedex (NASDAQ:PHMD) CEO Dolev Rafaeli unloaded 100,000 shares of PhotoMedex stock on the open market in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $14.94, for a total value of $1,494,000.00. Following the completion of the sale, the chief executive officer now directly owns 866,703 shares of the company’s stock, valued at approximately $12,948,543. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
PhotoMedex (NASDAQ:PHMD) traded up 0.13% on Wednesday, hitting $15.04. 173,274 shares of the company’s stock traded hands. PhotoMedex has a one year low of $10.51 and a one year high of $17.05. The stock’s 50-day moving average is $12.83 and its 200-day moving average is $14.46. The company has a market cap of $300.5 million and a price-to-earnings ratio of 15.17.
PhotoMedex (NASDAQ:PHMD) last announced its earnings results on Wednesday, November 6th. The company reported $0.11 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.32 by $0.21. The company had revenue of $45.90 million for the quarter, compared to the consensus estimate of $58.24 million. On average, analysts predict that PhotoMedex will post $0.99 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of PhotoMedex from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, January 7th. They now have a $13.90 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of PhotoMedex from $25.00 to $17.00 in a research note to investors on Thursday, November 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $16.97.
PhotoMedex, Inc (NASDAQ:PHMD) is a Global Skin Health Solutions company that provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.